Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of vanzacaftor + tezacaftor + deutivacaftor in cystic fibrosis
NL-OMON53726Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started Apr 2023; status: recruiting.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON53726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53726.